OM
OKUR

Opaleye Management’s OnKure Therapeutics OKUR Stock Holding History

Opaleye Management’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-16,500
Closed -$249K – 57
2024
Q2 		$249K Buy
+16,500
New +$280K 0.06% 51

Other funds holding OKUR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management's OKUR Position: Q3 2024 in Review

Opaleye Management sold out of OnKure Therapeutics (OKUR) in Q3 2024, closing a stake of 16,500 shares — an estimated $249K sold.

Opaleye Management first reported a position in OKUR in Q2 2024 and held it in 1 quarter. The position peaked at $249K in Q2 2024. 51 funds tracked by Wall St. Rank hold OKUR as of Q3 2024.

  • Opaleye Management reported no remaining OnKure Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Opaleye Management sold 16,500 OnKure Therapeutics shares in Q3 2024, an estimated $249K.
  • Opaleye Management first reported a position in OnKure Therapeutics in Q2 2024 and held it in 1 quarter.
  • Opaleye Management's OnKure Therapeutics position peaked at $249K in Q2 2024.
  • 51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q3 2024.

Based on Opaleye Management's 13F filing for Q3 2024, filed 14 Nov 2024.